Publications by authors named "George C Canas"
Article Synopsis
- Lorlatinib, a drug for ALK-positive metastatic non-small cell lung cancer, was studied to assess its safety and pharmacokinetics in patients with different levels of renal impairment.
- The study involved 29 participants divided into groups based on their renal function, and the results showed that lorlatinib was generally well tolerated, with no serious adverse events reported.
- It was found that dose adjustments are not needed for mild and moderate renal impairment, but those with severe renal impairment should reduce the dose from 100 mg to 75 mg daily.